In this podcast, Dr. Jerry Teitel explores how gene therapy for hemophilia A and hemophilia B might be delivered to patients across Canada in an equitable way, even though the administration will occur in only some sites. He describes the follow-up that is required in the critical months following administration to get the best results possible. Dr. Teitel is a Professor of Medicine at the University of Toronto, and Medical Director of the Hemophilia Treatment Program at St. Michael’s Hospital in Toronto, Ontario.
Canadian Hemophilia Society
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this podcast, Dr. Jerry Teitel explores how gene therapy for hemophilia A and hemophilia B might be delivered to patients across Canada in an equitable way, even though the administration will occur in only some sites. He describes the follow-up that is required in the critical months following administration to get the best results possible. Dr. Teitel is a Professor of Medicine at the University of Toronto, and Medical Director of the Hemophilia Treatment Program at St. Michael’s Hospital in Toronto, Ontario.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.